The magnitude of the anti-angiogenic and anti-tumor effects of erythropoietin blockade using R103A-EPO expression is comparable to that achieved by targeting VEGF in window chambers in our previous experiments [2], [5]. This evidence concerns the gene EPO and neoplasm.